ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and ...
Tuesday, OpGen Inc (NASDAQ:OPGN) shares are trading higher after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E ...
Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens European Investment Bank approves business combination transaction $9.4 million interim financing ...
The OpGen Gene Panel product tests for causes of antimicrobial and antibiotic resistance in hospital patients. The FDA approval, CEO Oliver Schacht said, will help it move away from research and ...
ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company’s board of directors has approved a 1-for-10 reverse stock split ...
OpGen ( (OPGN)) has provided an announcement. OpGen, Inc. appoints Mohd Azham Azudin as COO and Gillian Tan Rou Yee as Company Secretary, bringing extensive experience in private equity and corporate ...
Total revenue for 2022 was approximately $2.6 million Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million Conference call to be held March 29, 2023 at ...
PREPLEX project is part of broader InfectoGnostics Research Campus in Jena, Germany Total project volume of PREPLEX collaborative research is approximately $ 0.9 Mio ROCKVILLE, Md., April 03, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results